Tenax-Aurum-Treaty: How much money?
The Tenax-Aurum-Deal is a development and commercialization treaty for a new stroke therapy with Oxycyte (drug owned by Tenax). Aurum Biosciences, the brain imaging company in Glasgow, UK, will take this therapy into a phase 2a trial in Q1 2018. It is the absolutely only existing therapy, that can deliver oxygen to brain tissue in penumbra. Therefore, this therapy is likely to become a super-blockbuster like Enbrel, Remicade, Mabthera, or Lantus - all between $ 6 and $ 10 billion. Go to “aurumbiosciences.com > Investor Information” and you will find the following facts: “Aurum also signed a major research, development and commercialization deal with its US partner, Tenax Therapeutics, to develop Oxycyte, initially in the lead stroke indication. Tenax has granted Aurum full rights to develop and commercialize the product. Under the terms of this deal, the companies will share the benefits in stroke."
Until last week, the same information figured on the Tenax homepage. But then it was surprisingly deleted by Michael B. Jebsen, interim CEO of Tenax. Instead of confirming the upcoming clinical study, he seems to be saying: There is no Oxycyte and no treaty with Aurum, there will be no phase 2a trial and no revenues. That’s almost a little bit unpleasant, because it’s about billions, not millions. Luckily, Mr. Jebsen is a very, very nice man, who is always working very, very hard in the very, very best interest of his very, very dear shareholders. He’s therefore certainly willing to stroll around in his office and to throw a look in all drawers and to find and bring back the missing Tenax-Aurum-Treaty. Meanwhile, let all shareholders come together and form the shareholder’s choir. Let us give some moral support to our darling Michael B. Jebsen and sing for him as follows:
Michael, bring back
Oh, bring back my Treaty to me, to me!
Michael, bring back
Oh, bring back my Treaty to me!
